OPTNOptinoseOPTN info
$0.42info0.55%24h
Global rank24055
Market cap$47.65M
Change 7d-7.96%
YTD Performance-66.33%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Optinose (OPTN) Stock Overview

    OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

    OPTN Stock Information

    Symbol
    OPTN
    Address
    1020 Stony Hill RoadYardley, PA 19067United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://www.optinose.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    267 364 3500

    Optinose (OPTN) Price Chart

    -
    Value:-

    Optinose Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.42429999
    N/A
    Market Cap
    $47.65M
    N/A
    Shares Outstanding
    112.31M
    N/A
    Employees
    141.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org